Gladstone Capital Management LLP Invests $1.45 Million in The Cooper Companies, Inc. (NASDAQ:COO)

Gladstone Capital Management LLP bought a new position in The Cooper Companies, Inc. (NASDAQ:COO) during the second quarter, according to its most recent filing with the SEC. The firm bought 16,600 shares of the medical device company’s stock, valued at approximately $1,449,000. Cooper Companies makes up 0.1% of Gladstone Capital Management LLP’s investment portfolio, making the stock its 16th largest holding.

Several other hedge funds have also bought and sold shares of COO. EverSource Wealth Advisors LLC boosted its stake in Cooper Companies by 4.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 5,611 shares of the medical device company’s stock valued at $524,000 after purchasing an additional 264 shares during the last quarter. ProShare Advisors LLC boosted its position in shares of Cooper Companies by 7.7% during the second quarter. ProShare Advisors LLC now owns 28,896 shares of the medical device company’s stock valued at $2,523,000 after buying an additional 2,078 shares during the last quarter. Kayne Anderson Rudnick Investment Management LLC grew its holdings in Cooper Companies by 3.0% during the second quarter. Kayne Anderson Rudnick Investment Management LLC now owns 7,820,590 shares of the medical device company’s stock worth $682,738,000 after buying an additional 231,155 shares in the last quarter. Westwood Holdings Group Inc. raised its position in Cooper Companies by 9.6% in the 2nd quarter. Westwood Holdings Group Inc. now owns 201,651 shares of the medical device company’s stock valued at $17,604,000 after buying an additional 17,639 shares during the last quarter. Finally, Sei Investments Co. raised its position in Cooper Companies by 15.6% in the 2nd quarter. Sei Investments Co. now owns 266,841 shares of the medical device company’s stock valued at $23,296,000 after buying an additional 36,039 shares during the last quarter. Institutional investors and hedge funds own 24.39% of the company’s stock.

Insider Transactions at Cooper Companies

In related news, CEO Albert G. White III sold 114,992 shares of the business’s stock in a transaction on Thursday, September 19th. The stock was sold at an average price of $110.53, for a total transaction of $12,710,065.76. Following the sale, the chief executive officer now directly owns 165,273 shares in the company, valued at approximately $18,267,624.69. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, CEO Albert G. White III sold 114,992 shares of the company’s stock in a transaction dated Thursday, September 19th. The stock was sold at an average price of $110.53, for a total transaction of $12,710,065.76. Following the sale, the chief executive officer now directly owns 165,273 shares in the company, valued at $18,267,624.69. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CAO Agostino Ricupati sold 1,601 shares of the stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $108.03, for a total transaction of $172,956.03. Following the completion of the sale, the chief accounting officer now directly owns 4,818 shares in the company, valued at $520,488.54. The disclosure for this sale can be found here. Insiders sold 256,373 shares of company stock valued at $27,637,427 over the last three months. Company insiders own 2.00% of the company’s stock.

Cooper Companies Trading Down 0.5 %

Shares of Cooper Companies stock opened at $110.49 on Monday. The stock has a market capitalization of $22.00 billion, a P/E ratio of 64.99, a P/E/G ratio of 2.60 and a beta of 0.98. The Cooper Companies, Inc. has a 52-week low of $75.93 and a 52-week high of $112.38. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.18 and a current ratio of 1.99. The stock’s 50-day simple moving average is $97.93 and its 200 day simple moving average is $95.45.

Cooper Companies (NASDAQ:COO) last announced its quarterly earnings results on Wednesday, August 28th. The medical device company reported $0.96 EPS for the quarter, beating analysts’ consensus estimates of $0.91 by $0.05. Cooper Companies had a net margin of 9.45% and a return on equity of 9.08%. The company had revenue of $1 billion for the quarter, compared to analysts’ expectations of $997.30 million. During the same period in the prior year, the company posted $0.84 EPS. Cooper Companies’s revenue was up 7.8% compared to the same quarter last year. As a group, research analysts anticipate that The Cooper Companies, Inc. will post 3.66 EPS for the current year.

Analysts Set New Price Targets

Several analysts have recently issued reports on COO shares. Piper Sandler upped their target price on shares of Cooper Companies from $115.00 to $120.00 and gave the stock an “overweight” rating in a research note on Thursday, August 29th. Jefferies Financial Group upgraded shares of Cooper Companies from a “hold” rating to a “buy” rating and increased their price objective for the company from $107.00 to $115.00 in a research note on Tuesday, July 16th. Stifel Nicolaus reissued a “buy” rating and set a $115.00 target price (up previously from $110.00) on shares of Cooper Companies in a research report on Thursday, August 29th. Morgan Stanley upped their target price on Cooper Companies from $95.00 to $104.00 and gave the company an “equal weight” rating in a report on Tuesday, September 10th. Finally, Robert W. Baird increased their price target on Cooper Companies from $118.00 to $125.00 and gave the company an “outperform” rating in a research report on Thursday, August 29th. Four research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $115.00.

Cooper Companies Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.